Articles tagged "Graft function"

2022 American Transplant Congress
Kidney Grafts with Poor 24-Month Function Present Upregulated Immune Activity at Pre-Transplantation
E. Bardhi¹, K. Archer², D. Maluf¹, J. McDaniels¹, T. Rousselle¹, E. Akalin³, T. Mueller⁴, V. Mas¹
¹University of Maryland, Baltimore, MD, ²Ohio State University, Columbus, OH, ³Montefiore Medical Center, Bronx, NY, ⁴University Hospital Zürich, Zürich, Switzerland
*Purpose: A transcriptomic profile serves as a snapshot of the temporary cell state and thus, analyzing pretransplant kidney biopsies can provide detailed information on the…
2022 American Transplant Congress
Early Experience with 4-drug Maintenance Immunosuppression in Kidney and Pancreas Transplant Recipients
S. Mouawad¹, C. Shoemaker², J. Geyston³, A. Nishio Lucar³
¹University of Virginia Health System, Charlottesville, VA, ²Pharmacy, UVA Health, Charlottesville, VA, ³University of Virginia, Charlottesville, VA
*Purpose: Belatacept based immunosuppression regimens in kidney transplant recipients have been associated with better kidney function, improved metabolic profile, less de novo DSA formation and…
2022 American Transplant Congress
Normal Saline vs Electrolyte-a Use Peri- and Post-Operatively in Adult Kidney Transplant Recipients
K. R. Szempruch, A. D. Martschenko, H. Arora, R. Isaak, R. Prasad, P. Serrano
UNC Medical Center, Chapel Hill, NC
*Purpose: 0.9% normal saline (NS) has been used as the standard fluid replacement in kidney transplant recipients (KTRs) to prevent dehydration and to improve renal…
2022 American Transplant Congress
Defining the Characteristics and Graft Outcomes of Kidney Transplant Recipients with Pre-Transplant Elevated Plasma Oxalate Levels
D. Khan, N. Zhang, M. Keddis
Mayo Clinic, Scottsdale, AZ
*Purpose: The objective of this study is to compare graft outcomes for patients with pre-transplant elevated plasma oxalate (Pox) compared to a matched cohort.*Methods: Kidney…
2022 American Transplant Congress
A Sign of Things to Come? Clinical Markers After Elevated Donor-Derived Cell-Free DNA in Heart Transplant Recipients
D. T. Kim¹, E. J. Henricksen², B. M. Zhang³, J. J. Teuteberg¹, Y. Moayedi⁴, H. I. Luikart¹, J. Han⁵, B. Wayda¹, K. Khush¹
¹Cardiology, Stanford University, Stanford, CA, ²Transplant, Stanford Health Care, Stanford, CA, ³Pathology, Stanford University, Stanford, CA, ⁴Cardiology, University Health Network, Toronto, ON, Canada, ⁵Cardiology, University of Chicago, Chicago, IL
*Purpose: Endomyocardial biopsy (EMBx) has historically been the standard of care for surveillance post heart transplant (HTx), but is limited by sample area and interpretation.…
2022 American Transplant Congress
Single Nuclei RNA-Sequencing Identifies Distinct Cell Profile in Kidney Allografts with Recurrent Focal Segmental Glomerular Sclerosis (FSGS)
L. Gallon¹, E. Bardhi², J. McDaniels², A. Shetty², P. Hallack¹, C. Kuscu³, C. Kuscu³, T. Rousselle², J. Eason³, D. Maluf², V. Mas²
¹NWU, Chicago, IL, ²University of Maryland, Baltimore, MD, ³UTHSC, Memphis, TN
*Purpose: Strong evidence suggests that primary FSGS is due to a plasma factor that results in general podocyte dysfunction and risk of recurrence after kidney…
2022 American Transplant Congress
Impact of Varying Levels of Normal Range Baseline Donor Derived Cell Free DNA on Medium-Term Outcomes Following Kidney Transplantation
K. K. Sureshkumar¹, A. Grazier², B. Chopra¹
¹Nephrology, Medicine Institute, Allegheny General Hospital, Pittsburgh, PA, ²Abdominal Transplantation, Allegheny General Hospital, Pittsburgh, PA
*Purpose: Donor derived cell free DNA (dd-cfDNA) is a biomarker with high negative predictive value for ruling out acute rejection (AR) in kidney allografts. Baseline…
2022 American Transplant Congress
Generation and Functional Characterization of Bio-Engineered Livers for Heterotopic Implantation in Porcine Model of Acute Liver Failure
A. A. Katane¹, B. P. Amiot², A. R. Stumbras¹, A. Mendenhall¹, N. R. Palumbo¹, A. C. Donepudi¹, J. J. Ross¹, S. L. Nyberg³
¹Miromatrix Medical Inc, Eden Prairie, MN, ²Department of Surgery, Mayo Clinic, Rochester, MN, ³William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN
*Purpose: Liver transplantation has shown to be an effective therapy for the end-stage liver diseases (ESLD). However, as donor organ shortages increase, organ engineering technology…
2022 American Transplant Congress
Outcomes After Deceased Donor Kidney Transplantation Utilizing Kidney Allografts with Marginal Perfusion Parameters: A Single-Center Experience
P. N. Chotai¹, A. Logan², F. Siddiqui³, A. Schenk⁴, G. Bumgardner⁵, G. L. Brock², A. El-Hinnawi⁵, A. Rajab⁶, K. Washburn⁷, N. Singh²
¹Division of Transplantation, Department of General Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³Ohio State University, Bloomfield, NJ, ⁴Ohio State University Wexner Medical Center, Bexley, OH, ⁵Ohio State University, Columbus, OH, ⁶Ohio State University Wexner Medical Center, Columbus, OH, ⁷The Ohio State University, Columbus, OH
*Purpose: To study outcomes of deceased donor kidney transplantation (DDKT) in recipients of kidney allografts with poor perfusion parameters.*Methods: This is a retrospective, single center…
2022 American Transplant Congress
High Incidence Of Anti-HLA DSA And Late Allograft Dysfunction In Solid Organ Transplant Recipients Hospitalized With Covid-19
J. T. Killian, S. Roman Soto, V. Hauptfeld-Dolejsek, E. B. Levitan, P. M. Porrett, V. Kumar, F. E. Lund, J. A. Houp
University of Alabama at Birmingham, Birmingham, AL
*Purpose: Solid organ transplant (SOT) recipients admitted for COVID-19 commonly experience immunosuppression reduction and acute allograft dysfunction. Given the number of SOT patients hospitalized for…